Navidea Stock Gains After FDA Grants End Of Phase 2 Meeting To Discuss Rheumatoid Arthritis Program

by Vandana Singh, Benzinga Editor

July 15, 2021 8:48 AM | 1 min read |

The FDA has granted Navidea Biopharmaceuticals Inc's NAVB request for an End-of-Phase 2 Type B meeting to discuss its ongoing program in Rheumatoid Arthritis and advancement to the Phase 3 trial.
The meeting will take place on September 1 via conference call.
The meeting will be centered on a discussion of results from Phase 2b NAV3-31 study of Tc99m tilmanocept imaging.
The Phase 3 trial will establish the ability of Tc99m tilmanocept imaging to serve as an early predictor of treatment response in RA patients switching to an anti-TNFα therapy.
Price Action: NAVB shares are up 9.92% at $1.99 during the premarket session on the last check Thursday.
Related content: Benzinga's Full FDA Calendar.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.